# US 2008/0302372 A1 · Methods for pre-stressing and capping bioprosthetic tissue

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0302372 A1
- Document ID: US20080302372A1
- Status: Published application
- Kind: A1
- Application number: 12/135,507
- Filed: 2008-06-09
- Published: 2008-12-11
- Earliest claimed: 2007-06-11
- Assignees: Edwards Lifesciences Corporation
- Inventors: Jim Davidson; Jeff Dove; Darin Dobler
- Web page: https://patentgrep.com/patent/US20080302372A1

## CPC

- A61L 27/3625: {Vascular tissue, e.g. heart valves}
- A61F 2/2412: {with soft flexible valve members, e.g. tissue valves shaped like natural valves}
- A61L 27/3683: {subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment}
- A61L 27/3687: {characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents}
- A61L 27/3691: {characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation}
- A61L 27/507: {for artificial blood vessels (apparatus for applying cells on a blood vessel prosthesis A61F2/062)}
- A61F 2210/0004: bioabsorbable
- A61F 2210/0076: multilayered, e.g. laminated structures
- A61L 2400/02: Treatment of implants to prevent calcification or mineralisation in vivo
- A61L 2430/20: for reconstruction of the heart, e.g. heart valves
- A61L 2430/40: Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)

## Abstract

A treatment for bioprosthetic tissue used in implants or for assembled bioprosthetic heart valves to reduce in vivo calcification is disclosed. The method includes preconditioning, pre-stressing, or pre-damaging fixed bioprosthetic tissue in a manner that mimics the damage associated with post-implant use, while, and/or subsequently applying a calcification mitigant such as a capping agent or a linking agent to the damaged tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the damage process (service stress) and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. The linking agent will act as an elastic reinforcement or shock-absorbing spring element in the tissue structure at the site of damage from the pre-stressing. In one method, tissue leaflets in assembled bioprosthetic heart valves are preconditioned by simulating actual flow conditions for a predetermined number of cycles, during or after which the valve is exposed to the capping agent.

## Claims

### Claim 1

A method of treating bioprosthetic implant tissue to reduce in vivo calcification, comprising:
at least partially cross-linking bioprosthetic implant tissue; then
stressing the cross-linked tissue; and
applying a calcification mitigant to the stressed, cross-linked tissue.

### Claim 2 (depends on 1)

The method of claim 1, wherein the calcification mitigant comprises a capping agent solution having at least one constituent that can bind to calcium, phosphate, or immunogenic factor binding sites.

### Claim 3 (depends on 1)

The method of claim 1, wherein the calcification mitigant comprises a linking agent solution including a long elastic molecule.

### Claim 4 (depends on 1)

The method of claim 1, wherein the calcification mitigant comprises a capping agent selected from the group consisting of:
an amine,
an amino acid,
an amino sulfonate,
a hydrophilic multifunctional polymer,
a hydrophobic multifunctional polymer,
α-dicarbonyl,
a hydrazides,
a N,N-disuccinimidyl carbonate,
a carbodiimide,
2-chloro-1-methylpyridinium iodide (CMPI),
an antibiotic,
a cell recruiting agent,
a hemocompatibility agent,
an antiinflammatory agent,
an antiproliferative agent,
an immunogenic suppressing agent,
a reducing agent, and
a mono-, di- or polyepoxy alkane.

### Claim 5 (depends on 1)

The method of claim 1 where the calcification mitigant is delivered in one or a combination of the selected solutions:
an aqueous solution,
an organic solvent, and
an organic buffered solution.

### Claim 6 (depends on 1)

The method of claim 1 where the tissue is fully cross-linked prior to stressing.

### Claim 7 (depends on 1)

The method of claim 1 where the tissue comprises pre-cut heart valve leaflets mounted and flexed in a suitable flow producing apparatus.

### Claim 8 (depends on 1)

The method of claim 1 where the tissue comprises bulk sheets of tissue flexed in a suitable apparatus.

### Claim 9 (depends on 1)

The method of claim 1, wherein the bioprosthetic implant tissue comprises a bioprosthetic heart valve, and the step of stressing comprises subjecting the heart valve to pulsed fluid flow therethrough.

### Claim 10 (depends on 9)

The method of claim 9, wherein the heart valve is subjected to pulsed fluid flow for at least 100 cycles.

### Claim 11 (depends on 9)

The method of claim 9, wherein the step of stressing comprises subjecting the bioprosthetic implant tissue to a simulated post-implant physiological environment.

### Claim 12 (depends on 9)

The method of claim 9, wherein the step of stressing comprises subjecting the bioprosthetic implant tissue to at least one stress-accelerating environmental parameter.

### Claim 13 (depends on 12)

The method of claim 12 wherein the stress-accelerating environmental parameter comprises rapid pulsed fluid flow in a range of 4-1500 Hz.

### Claim 14 (depends on 12)

The method of claim 12 wherein the stress-accelerating environmental parameter is an elevated temperature range of 26-65° C.

### Claim 15 (depends on 12)

The method of claim 12 wherein the stress-accelerating environmental parameter is an acidic solution of pH of 4-7.

### Claim 16 (depends on 12)

The method of claim 12 wherein the stress-accelerating environmental parameter is an alkaline solution of pH 8-10.

### Claim 17 (depends on 12)

The method of claim 12 wherein the stress-accelerating environmental parameter is an oxidizing solution.

### Claim 18 (depends on 12)

The method of claim 12 wherein the stress-accelerating environmental parameter comprises at least two selected from the group consisting of:
rapid pulsed fluid flow in a range of 4-1500 Hz;
an elevated temperature range of 26-65° C.;
an acidic solution of pH of 4-7;
an alkaline solution of pH 8-10; and
an oxidizing solution.

### Claim 19 (depends on 1)

The method of claim 1 wherein the step of stressing is done until the newly exposed sites to be capped on the bioprosthetic tissue increase by at least 10%.

### Claim 20 (depends on 1)

The method of claim 1 wherein the step of stressing is done at least until the level of damage in the bioprosthetic implant tissue increases by about 10%.

### Claim 21 (depends on 1)

The method of claim 1 wherein the step of stressing is done at least until the rate of acid production in the bioprosthetic implant tissue decreases by about 10%.

### Claim 22 (depends on 1)

The method of claim 1, wherein the steps of first stressing the tissue and then applying a calcification mitigant thereto are done multiple times.

### Claim 23 (depends on 1)

The method of claim 1, wherein the steps of first stressing the tissue and then applying a calcification mitigant thereto are done at least twice with different calcification mitigants.

### Claim 24

A method of treating bioprosthetic implant tissue to reduce in vivo calcification, comprising:
cyclic stressing the bioprosthetic implant tissue until the rate of acid production in the bioprosthetic implant tissue decreases by about 10%; then
applying a calcification mitigant to the stressed tissue.

### Claim 25 (depends on 24)

The method of claim 24, wherein the bioprosthetic implant tissue comprises a bioprosthetic heart valve, and the step of stressing comprises subjecting the heart valve to pulsed fluid flow therethrough.

### Claim 26 (depends on 24)

The method of claim 24, wherein the step of stressing is done until the rate of increase of the acid level of the bioprosthetic implant tissue levels off.

### Claim 27 (depends on 24)

The method of claim 24, wherein the calcification mitigant comprises a capping agent solution having at least one constituent that can bind to calcium or phosphate, and/or immunogenic binding sites.

### Claim 28 (depends on 24)

The method of claim 24, wherein the calcification mitigant comprises a capping agent selected from the group consisting of:
an amine,
an amino acid,
an amino sulfonate,
a hydrophilic multifunctional polymer,
a hydrophobic multifunctional polymer,
α-dicarbonyl,
a hydrazides,
a N,N-disuccinimidyl carbonate,
a carbodiimide,
2-chloro-1-methylpyridinium iodide (CMPI),
an antibiotic,
a cell recruiting agent,
a hemocompatibility agent,
an antiinflammatory agent,
an antiproliferative agent,
an immunogenic suppressing agent,
a reducing agent, and
a mono-, di- or polyepoxy alkane.

### Claim 29 (depends on 24)

The method of claim 24, wherein the calcification mitigant comprises a linking agent solution including a long elastic molecule.

### Claim 30

A method of treating a bioprosthetic heart valve to reduce in vivo calcification, comprising:
mounting a bioprosthetic heart valve in a simulated fluid flow system;
subjecting the bioprosthetic heart valve to pulsed fluid flow for at least 100 cycles; then
applying a calcification mitigant to the bioprosthetic heart valve.

### Claim 31 (depends on 30)

The method of claim 30, wherein the bioprosthetic heart valve is subjected to pulsed fluid flow for at least 100,000 cycles.

### Claim 32 (depends on 30)

The method of claim 30, wherein the steps of first subjecting the bioprosthetic heart valve to pulsed fluid flow and then applying a calcification mitigant thereto are done multiple times.

### Claim 33 (depends on 30)

The method of claim 30, wherein the steps of first subjecting the bioprosthetic heart valve to pulsed fluid flow and then applying a calcification mitigant thereto are done at least twice with different calcification mitigants.

### Claim 34 (depends on 30)

The method of claim 30, wherein the step of subjecting is done until the rate of increase of the acid level of the bioprosthetic implant tissue levels off.

### Claim 35 (depends on 30)

The method of claim 30, wherein the calcification mitigant comprises a capping agent solution having at least one constituent that can bind to calcium, phosphate, or immunogenic factor binding sites.

### Claim 36 (depends on 30)

The method of claim 30, wherein the calcification mitigant comprises a linking agent solution including a long elastic molecule.
